HomeBUSINESS
BUSINESS

Empliciti Shows Positive Response in Newly Diagnosed Japanese Myeloma Patients: BMS
(Dec.12.2017)

Bristol-Myers Squibb’s monoclonal antibody Empliciti (elotuzumab) hit the primary endpoint in a PII study enrolling Japanese patients newly diagnosed with multiple myeloma (MM), the company’s Japan unit said on December 11 ...
(LOG IN FOR FULL STORY)